Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CFO Sells $72,360.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CFO Bo Kruse sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $18.09, for a total transaction of $72,360.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Bo Kruse also recently made the following trade(s):

  • On Friday, October 22nd, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.94, for a total transaction of $103,760.00.
  • On Monday, October 4th, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $28.78, for a total transaction of $115,120.00.
  • On Wednesday, September 22nd, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $30.82, for a total transaction of $123,280.00.
  • On Tuesday, September 7th, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $32.03, for a total transaction of $128,120.00.

YMAB stock opened at $17.73 on Thursday. The company has a market capitalization of $773.81 million, a P/E ratio of -19.06 and a beta of 1.08. Y-mAbs Therapeutics, Inc. has a 12 month low of $16.40 and a 12 month high of $55.00. The business has a 50 day simple moving average of $26.73.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Thursday, November 4th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.08). The firm had revenue of $8.97 million for the quarter, compared to the consensus estimate of $10.87 million. Y-mAbs Therapeutics had a negative return on equity of 19.08% and a negative net margin of 83.21%. During the same period in the prior year, the company posted ($0.82) earnings per share. As a group, equities research analysts forecast that Y-mAbs Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Several equities research analysts have recently weighed in on YMAB shares. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 10th. JPMorgan Chase & Co. downgraded shares of Y-mAbs Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $57.00 to $30.00 in a report on Tuesday, November 16th. HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, October 8th. Finally, Morgan Stanley assumed coverage on shares of Y-mAbs Therapeutics in a research note on Friday, November 19th. They issued an “equal weight” rating and a $25.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Y-mAbs Therapeutics currently has an average rating of “Buy” and an average price target of $49.00.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Y-mAbs Therapeutics by 13.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 103,634 shares of the company’s stock worth $2,958,000 after buying an additional 12,008 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in shares of Y-mAbs Therapeutics by 322.1% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 6,449 shares of the company’s stock worth $184,000 after buying an additional 4,921 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Y-mAbs Therapeutics during the 3rd quarter valued at $49,000. Jane Street Group LLC acquired a new position in Y-mAbs Therapeutics during the 3rd quarter valued at $523,000. Finally, Brookfield Asset Management Inc. raised its stake in Y-mAbs Therapeutics by 7.5% during the 3rd quarter. Brookfield Asset Management Inc. now owns 179,236 shares of the company’s stock valued at $5,115,000 after purchasing an additional 12,582 shares during the last quarter. 59.92% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

See Also: Why is the Consumer Price Index (CPI) important?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.